|
|
 |
|
Other
Randomized Phase III Trial Comparing 16 to 18 weeks of Neoadjuvant Exemestane (25mg daily), Letrozole (2.5mg) or Anastrozole (1mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Breast Cancer
ACOSOG Z1031 - PDF
Trial of Fulvestrant with or without Lapatinib for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer
CALGB 40302 - PDF
An Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older with Operable, Newly Diagnosed Breast Cancer
CALGB 369901 - PDF
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
E5103 - PDF
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer
NSABP B-42 - PDF
PACCT-1 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
PACCT1 - PDF
« Back | Top
|
|
|
|
|
|
